Key result
Pre-MI intramyocardial PEDF gene delivery improves microvascular reperfusion and prevents no-reflow in preclinical MI.
Answers are grounded in this paper and cite their sources.
The phenomenon of no-reflow seriously limits the therapeutic value of coronary recanalization and leads to poor prognosis. Recent studies have demonstrated the potential role of pigment epithelium-derived factor (PEDF) in stabilizing endothelial cell junction, reducing vascular permeability and maintaining a quiescent vasculature. In this study, intramyocardial gene delivery was performed 5 days before the acute myocardial infarction/recanalization experiment in male rats. Positron emission tomography perfusion imaging with 13 N-NH 3 indicated PEDF to promote microvascular reperfusion significantly 4 h postcoronary occlusion. PEDF was observed to maintain the stability of endothelial adherens junctions (AJs), thus preventing the occurrence of no-reflow. PEDF reduced the hypoxia-induced vascular endothelial (VE)-cadherin endocytosis through PEDF/LR/Src/VE-cadherin S665 axis in vitro , which was remarkably observed to maintain endothelial AJs. Generally, PEDF might function as a relevant target for therapeutic vasculoprotection by way of regulating the phosphorylation level of VE-cadherin according to our data, thus being crucial for preventing no-reflow.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied Acute myocardial infarction and coronary no-reflow. Intramyocardial gene delivery of pigment epithelium-derived factor (PEDF) was evaluated on Microvascular reperfusion on 13N-NH3 PET perfusion imaging and endothelial adherens junction stability. Intramyocardial PEDF gene delivery 5 days before acute MI significantly promoted microvascular reperfusion at 4 hours post-occlusion and prevented no-reflow in male rats.
Synapse has enriched 10 related papers. Consider them for comparative context: